BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16908139)

  • 41. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase.
    Charvat TT; Lee DJ; Robinson WE; Chamberlin AR
    Bioorg Med Chem; 2006 Jul; 14(13):4552-67. PubMed ID: 16524737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
    Petrocchi A; Jones P; Rowley M; Fiore F; Summa V
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4245-9. PubMed ID: 19523819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors.
    Jin H; Cai RZ; Schacherer L; Jabri S; Tsiang M; Fardis M; Chen X; Chen JM; Kim CU
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3989-92. PubMed ID: 16723225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.
    Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V
    J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel cAMP PDE III inhibitors: imidazo[4,5-b]pyridin-2(3H)-ones and thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs.
    Singh B; Bacon ER; Robinson S; Fritz RK; Lesher GY; Kumar V; Dority JA; Reuman M; Kuo GH; Eissenstat MA
    J Med Chem; 1994 Jan; 37(2):248-54. PubMed ID: 8295212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor.
    Vandurm P; Cauvin C; Guiguen A; Georges B; Le Van K; Martinelli V; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4806-9. PubMed ID: 19556126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
    Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
    Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors.
    Langley DR; Samanta HK; Lin Z; Walker MA; Krystal MR; Dicker IB
    Biochemistry; 2008 Dec; 47(51):13481-8. PubMed ID: 18991395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
    Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
    Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV integrase inhibitors as therapeutic agents in AIDS.
    Nair V; Chi G
    Rev Med Virol; 2007; 17(4):277-95. PubMed ID: 17503547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
    Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
    Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complete absolute configuration of integramide A, a natural, 16-mer peptide inhibitor of HIV-1 integrase, elucidated by total synthesis.
    De Zotti M; Formaggio F; Kaptein B; Broxterman QB; Felock PJ; Hazuda DJ; Singh SB; Brückner H; Toniolo C
    Chembiochem; 2009 Jan; 10(1):87-90. PubMed ID: 18850604
    [No Abstract]   [Full Text] [Related]  

  • 54. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity.
    Al-Mawsawi LQ; Sechi M; Neamati N
    FEBS Lett; 2007 Mar; 581(6):1151-6. PubMed ID: 17328897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
    Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
    Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen-Schmidt condensation, displaying diverse biological activities as curcumin analogues.
    Cao B; Wang Y; Ding K; Neamati N; Long YQ
    Org Biomol Chem; 2012 Feb; 10(6):1239-45. PubMed ID: 22179573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficient synthesis and utilization of phenyl-substituted heteroaromatic carboxylic acids as aryl diketo acid isosteres in the design of novel HIV-1 integrase inhibitors.
    Zeng LF; Zhang HS; Wang YH; Sanchez T; Zheng YT; Neamati N; Long YQ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4521-4. PubMed ID: 18662877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species.
    Summa V; Petrocchi A; Matassa VG; Gardelli C; Muraglia E; Rowley M; Paz OG; Laufer R; Monteagudo E; Pace P
    J Med Chem; 2006 Nov; 49(23):6646-9. PubMed ID: 17154493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis.
    Al-Mawsawi LQ; Christ F; Dayam R; Debyser Z; Neamati N
    FEBS Lett; 2008 Apr; 582(10):1425-30. PubMed ID: 18331842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.